Lung cancer screening rates remain very low among current and former smokers

February 2, 2017

Lung cancer screening rates remained very low and unchanged among eligible populations in 2015, despite recommendations that high risk current and former smokers be screened. The study by American Cancer Society investigators appears in JAMA Oncology. The authors say it underscores the need to educate clinicians and those at risk about lung cancer screening.

In December 2013, the United States Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer using low-dose computed tomography (LDCT) for people ages 55 to 80 with at least a 30 pack-year smoking history (calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked). The recommendation came after the National Lung Screening Trial (NLST) showed screening this population could reduce lung cancer mortality 20% in this population.

In 2010, before the recommendation, the National Health Interview Survey (NHIS) found only 2% to 4% of high risk smokers received LCDT in the previous year.

To investigate further, researchers led by Ahmedin Jemal DVM, PhD, compared responses from the National Health Interview Survey between 2010 and 2015, including only those who would meet the requirements for screening under the USPSTF recommendation.

The study found the proportion of eligible current and former smokers who reported LCDT screening in the past 12 months remained low and constant between the two years, from 3.3% in 2010 to 3.9% in 2015. Based on those figures, the authors estimate that of the 6.8 million current and former smokers eligible for screening in 2015, only 262,700 received it.

"The reasons for the low uptake in screening are probably varied, and likely include lack of knowledge among both smokers and doctors as to screening recommendations as well as access to high quality screening," said Dr. Jemal. "Our previous study showed implementing quality screening broadly across the U.S. could prevent about 12,000 deaths every year in the short term. But we cannot prevent those deaths until and unless we start educating eligible smokers as well as clinicians about the benefits and risks of , so patients can make an informed decision."

Explore further: Report describes VHA clinical demonstration project for lung cancer screening

More information: JAMA Oncology, DOI: 10.1001/jamaoncol.2016.6416

Related Stories

Report describes VHA clinical demonstration project for lung cancer screening

January 30, 2017
Implementing a comprehensive lung cancer screening program was challenging and complex according to a new article published online by JAMA Internal Medicine that describes a lung cancer demonstration project conducted at ...

Risks of LDCT LC screenings need to be assessed in 20- to 29-pack-year smokers

October 19, 2015
The potential risks and harms of low-dose CT (LDCT) lung cancer screening in current 20- to 29-pack-year smokers needs to be assessed before recommending LDCT to this group, according to a study published October 19 in the ...

Diabetes proves deadly for smokers

November 22, 2016
While it is well known that smoking causes lung cancer, heavy smokers with diabetes are also at increased risk of death from causes other than lung cancer, according to a study being presented next week at the annual meeting ...

Study develops prediction model for lung cancer risk in never smokers

November 2, 2016
Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light and heavy smokers using a large Taiwanese prospective ...

Screening could avert 12,000 lung cancer deaths each year in the US

February 25, 2013
Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers has the potential to avert approximately 12,000 lung cancer deaths each year in the United States. That ...

Study highlights importance of regular lung cancer screenings for those at high risk

August 18, 2016
Lung cancer is the leading cause of cancer death for men and women. It is also one of the most complex cancers, both at the molecular level and through its clinical behavior. Screening is paramount as it helps physicians ...

Recommended for you

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.